Bennett R, Frawley T, Thompson PA, Whitechurch A, Khot A, Roberts AW, Seymour JF, Anderson MA, Ritchie D. A single‐institution study of allograft outcomes for chronic lymphocytic leukaemia over 20 years. Internal Medicine Journal. 2025;:10.1111/imj.70124
Tiong I-SS, Nguyen T, Chua CC, Teh CE, Muttiah C, Ftouni S, Seymour JF, Gray DHD, Roberts AW, Dawson S-J, Lindeman GJ, Blombery P. Emergent BAX-mutated clonal hematopoiesis after venetoclax-based therapy for breast cancer. Blood Advances. 2025;:10.1182/bloodadvances.2025016063
Bennett R, Juneja M, Anderson MA, Minson A, Herbert K, Lieschke GJ, Roberts AW, Mason KD, Seymour JF, Dickinson M. Routine magnetic resonance central nervous system imaging may be avoided in high-risk systemic diffuse large B-cell lymphoma with negative cerebrospinal fluid analyses. Leukemia & Lymphoma. 2025;66(6):10.1080/10428194.2025.2451725
Chua CC, Loo S, Fong CY, Ting SB, Tiong IS, Fleming S, Anstee NS, Ivey A, Ashby M, Teh T-C, Reynolds J, Roberts AW, Wei AH. Final analysis of the phase 1b Chemotherapy and Venetoclax in Elderly Acute Myeloid Leukemia Trial (CAVEAT). Blood Advances. 2025;9(8):10.1182/bloodadvances.2024014900
Peng H, Jabbari JS, Tian L, Wang C, You Y, Chua CC, Anstee NS, Amin N, Wei AH, Davidson N, Roberts AW, Huang D, Ritchie ME, Thijssen R. Single-cell Rapid Capture Hybridization sequencing to reliably detect isoform usage and coding mutations in targeted genes. Genome Research. 2025;35(4):10.1101/gr.279322.124
Gong J-N, Djajawi TM, Moujalled DM, Pomilio G, Khong T, Zhang L-P, Fedele PL, Low MS, Anderson MA, Riffkin CD, White CA, Lan P, Lessene G, Herold MJ, Strasser A, Spencer A, Grigoriadis G, Wei AH, van Delft MF, Roberts AW, Huang DCS. Re-appraising assays on permeabilized blood cancer cells testing venetoclax or other BH3 mimetic agents selectively targeting pro-survival BCL2 proteins. Cell Death & Differentiation. 2025;:10.1038/s41418-025-01487-7
Luo M-X, Tan T, Trussart M, Poch A, Nguyen TMH, Speed TP, Hicks DG, Bandala-Sanchez E, Peng H, Chappaz S, Slade C, Utzschneider DT, Koldej RM, Ritchie D, Strasser A, Thijssen R, Ritchie ME, Tam CS, Lindeman GJ, Huang DCS, Lew TE, Anderson MA, Roberts AW, Teh CE, Gray DHD. Venetoclax dose escalation rapidly activates a BAFF/BCL-2 survival axis in chronic lymphocytic leukemia. Blood. 2024;144(26):10.1182/blood.2024024341
Thiagarajah N, Dowling MR, Dunne K, Aarons D, Collins J, Tran S, Fleming S, Sutrave G, Hiwase D, Fong CY, Hsu B, Purtill D, Watson A-M, Kennedy GA, Stevenson WS, Larsen SR, Moore J, Perera T, Ritchie DS, Wei A, Roberts AW, Hamad N, Bajel A. Real-World Patterns of Care and Outcomes for Non-Favourable Risk Acute Myeloid Leukemia Treated with Intensive Chemotherapy across Australia and New Zealand- Data Linkage between the ALLG National Blood Cancer Registry (NBCR) and the Australia and New Zealand Transplant and Cellular Therapy (ANZTCT) Registry. Blood. 2024;144(Supplement 1):10.1182/blood-2024-209389
Loo S, Iland H, Tiong IS, Westerman D, Othman J, Marlton P, Chua CC, Purtill D, Rose H, Fleming S, Singhal D, Enjeti AK, Stevenson WS, Ng TF, Derek M, Vaughan L, Gasiorowski R, Ivey A, Souza A, Pattani R, Anstee NS, Koldej R, Ritchie DS, Loghavi S, Daver N, DiNardo CD, Roberts AW, Grove CS, Reynolds J, Wei AH. Revumenib As Pre-Emptive Therapy for Measurable Residual Disease in NPM1 mutated or KMT2A- rearranged Acute Myeloid Leukemia: A Domain of the Multi-Arm ALLG AMLM26 Intercept Platform Trial. Blood. 2024;144(Supplement 1):10.1182/blood-2024-202895
D’Sa S, Dimopoulos MA, Jurczak W, Marlton P, Mulligan SP, Wahlin BE, Sobieraj-Teague M, Roberts AW, Tam CS, Castillo JJ, Allewelt H, Prathikanti R, Chan WY, Tian T, Schneider J, Vezan R, Opat SS. Long-term Clinical Outcomes in Patients with Waldenström Macroglobulinemia (WM) Who Received Zanubrutinib in the Phase 3 ASPEN Study: A Report from the Zanubrutinib Extension Study. Blood. 2024;144(Supplement 1):10.1182/blood-2024-199276
